ArticleJournal of endocrinological investigation2025
miR-18a-3p modulates the progression of polycystic ovary syndrome by targeting CITED2 and PI3K/AKT signaling pathway.
Article in Journal of endocrinological investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePolycystic ovary syndrome (PCOS) severely affects fertility and quality of life in women of reproductive age. Research has shown that microRNAs (miRNAs) may play a role in the development of PCOS. This study focused on the clinical significance and potential function of miR-18a-3p in PCOS, aiming to find a new molecular marker for screening and progression prediction in PCOS.
methodsThe expression of miR-18a-3p was detected by real-time quantitative PCR. The function of miR-18a-3p on the phenotype of human ovarian granulosa cells (KGN) was assessed by cell counting kit-8 assay and apoptosis assay. The downstream mechanisms by which miR-18a-3p were explored by bioinformatics methods and dual-luciferase reporter assay. The effect of CITED2 expression on the function of miR-18a-3p in KGN cells was further examined.
resultsmiR-18a-3p was downregulated in the serum and follicular fluid of PCOS patients and showed clinical significance in screening for PCOS. Low levels of miR-18a-3p were associated with the level of HOMA-IR, LH, Testosterone, and AMH in PCOS patients. In KGN cells, the inhibition of miR-18a-3p expression promoted apoptosis and suppressed cell viability, whereas overexpression of miR-18a-3p exhibited the opposite effect. miR-18a-3p targeted and negatively modulated CITED2 to exert its effect in KGN cells. Furthermore, miR-18a-3p modulated the PI3K/AKT signaling pathway mediated by CITED2.
conclusionsDownregulation of miR-18a-3p demonstrates potential as a diagnostic marker for PCOS. miR-18a-3p affected the phenotype of KGN cells and modulated the PI3K/AKT signaling pathway through CITED2.
Indexed as
Identifiers
40716024What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.